Drug profile

The FDA adverse-event record for Bordetella, Parainfluenza, Adenovirus

85 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bordetella, Parainfluenza, Adenovirus. See the species affected, top reactions, and outcomes below.

85
adverse-event reports
9.4%
death-coded share
Dog
most-reported species
39
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
85
Total Reports
8
Deaths Reported
9.4%
Death Rate

Active Ingredients

Bordetella, Parainfluenza, Adenovirus

Administration Routes

NasalUnknownOralSubcutaneous

Species Affected

Dog 85

Most Affected Breeds

Retriever - Labrador 11
Chihuahua 6
Retriever - Golden 5
Terrier - Bull - American Pit 5
Shih Tzu 4
Boxer (German Boxer) 4
Crossbred Canine/dog 3
Terrier - Yorkshire 3
Terrier - Jack Russell 3
Terrier (unspecified) 3

Most Reported Reactions

Vomiting 39
Facial swelling (see also 'Skin') 25
Lethargy (see also Central nervous system depression in 'Neurological') 21
Hives (see also 'Skin') 21
Anaphylaxis 15
Pale mucous membrane 8
Seizure NOS 8
Fever 7
Drooling 7
Diarrhoea 7
Death 6
Panting 5

Outcome Breakdown

Ongoing
39 (45.9%)
Recovered/Normal
32 (37.6%)
Died
6 (7.1%)
Outcome Unknown
6 (7.1%)
Euthanized
2 (2.4%)

Bordetella, Parainfluenza, Adenovirus Adverse Event Insights

85 reports name Bordetella, Parainfluenza, Adenovirus; 8 recorded a death outcome (9.4% of reported events, not a population-level mortality rate). Active ingredient: Bordetella, Parainfluenza, Adenovirus. Administration routes: Nasal, Unknown, Oral, Subcutaneous.

By species: Dog (85 reports). By breed: Retriever - Labrador (11), Chihuahua (6), Retriever - Golden (5).

Leading clinical signs: Vomiting (39), Facial swelling (see also 'Skin') (25), Lethargy (see also Central nervous system depression in 'Neurological') (21), Hives (see also 'Skin') (21). Outcome, 85 coded reports: Ongoing leads at 45.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.